CH639852A5 - MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS. - Google Patents

MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS. Download PDF

Info

Publication number
CH639852A5
CH639852A5 CH692479A CH692479A CH639852A5 CH 639852 A5 CH639852 A5 CH 639852A5 CH 692479 A CH692479 A CH 692479A CH 692479 A CH692479 A CH 692479A CH 639852 A5 CH639852 A5 CH 639852A5
Authority
CH
Switzerland
Prior art keywords
sodium
urinary
strains
lysates
per liter
Prior art date
Application number
CH692479A
Other languages
French (fr)
Inventor
Jean-Claude Farine
Anne Rivkine
Isidro Bulto
Original Assignee
Om Laboratoires Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Laboratoires Sa filed Critical Om Laboratoires Sa
Priority to CH692479A priority Critical patent/CH639852A5/en
Priority to DE19803019448 priority patent/DE3019448A1/en
Priority to ES491920A priority patent/ES491920A0/en
Priority to FR8012677A priority patent/FR2462164A1/en
Priority to HU801726A priority patent/HU181725B/en
Priority to DD222593A priority patent/DD153192A5/en
Priority to RO80101780A priority patent/RO80054A/en
Priority to IT49314/80A priority patent/IT1143025B/en
Priority to BE0/201514A priority patent/BE884456A/en
Priority to PL1980225853A priority patent/PL127520B1/en
Priority to AR281940A priority patent/AR222887A1/en
Priority to CS805266A priority patent/CS212234B2/en
Priority to YU1896/80A priority patent/YU42532B/en
Priority to JP10231580A priority patent/JPS5622733A/en
Priority to GB8024420A priority patent/GB2054374B/en
Priority to PT71612A priority patent/PT71612A/en
Publication of CH639852A5 publication Critical patent/CH639852A5/en
Priority to HRP-1896/80A priority patent/HRP921282B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Description

La présente invention concerne un médicament contre des maladies infectieuses des voies urinaires et digestives, tel que défini dans la revendication 1. The present invention relates to a medicament against infectious diseases of the urinary and digestive tract, as defined in claim 1.

De préférence, les lysats proviennent de toutes les souches mentionnées dans la revendication 1. Preferably, the lysates come from all the strains mentioned in claim 1.

Les souches NCTC sont cataloguées par la National Collection of Type Cultures, Central Public Health Laboratory, Colindale Avenue, NW9 5HT Londres, et accessibles au public, tandis que les souches I ont été déposées par le titulaire du présent brevet le 7 mars 1979 auprès de la Collection nationale de culture de microorganismes, Institut Pasteur, 28, rue du Docteur-Roux. F-75724 Paris Cedex 15. The NCTC strains are cataloged by the National Collection of Type Cultures, Central Public Health Laboratory, Colindale Avenue, NW9 5HT London, and accessible to the public, while strains I were deposited by the holder of this patent on March 7, 1979 with the National Collection of Culture of Microorganisms, Institut Pasteur, 28, rue du Docteur-Roux. F-75724 Paris Cedex 15.

Les cultures bactériennes sont faites selon les techniques bactériologiques courantes, dans les conditions les mieux adaptées à la multiplication des germes. The bacterial cultures are made according to current bacteriological techniques, under the conditions best suited to the multiplication of germs.

Le traitement des cultures pour l'obtention des lysats se fait de préférence dans un milieu selon l'une des revendications 4 ou 5, en fermenteur par exemple à 35-37° C pendant 8-14 h, ou en flacons de Roux par exemple, à 33-37° C pendant 24-48 h. The treatment of the cultures for obtaining the lysates is preferably done in a medium according to one of claims 4 or 5, in a fermenter for example at 35-37 ° C for 8-14 h, or in bottles of Roux for example , at 33-37 ° C for 24-48 h.

Les cultures sont récoltées selon les méthodes usuelles. Les suspensions bactériennes ainsi obtenues sont dénombrées souche par souche et soumises à la lyse alcaline (pH 9 à 10) progressive à une température pouvant varier entre 20 et 40° C, avec, entre autres : soude caustique, potasse caustique, aminés primaires, secondaires et tertiaires. La lyse est poursuivie pendant 1 à 5 d sous contrôle microscopique. The cultures are harvested according to the usual methods. The bacterial suspensions thus obtained are counted strain by strain and subjected to alkaline lysis (pH 9 to 10) progressive at a temperature which can vary between 20 and 40 ° C, with, among others: caustic soda, caustic potash, primary and secondary amines and tertiary. Lysis is continued for 1 to 5 d under microscopic control.

Le volume des lysats de chaque souche bactérienne entrant dans le concentré final est calculé en fonction des résultats des dénombrements. The volume of lysates of each bacterial strain entering the final concentrate is calculated based on the results of the counts.

Le traitement des cultures pour l'obtention des lysats par autolyse se fait de préférence dans un milieu selon la revendication 6. The treatment of the cultures for obtaining the lysates by autolysis is preferably carried out in a medium according to claim 6.

Les cultures ensemencées sont incubées pendant 3 mois à 37° C. Le surnageant filtré de ces cultures constitue le lysat. The seeded cultures are incubated for 3 months at 37 ° C. The filtered supernatant from these cultures constitutes the lysate.

Préparation du concentré de lysats bactériens Preparation of the bacterial lysate concentrate

Les lysats de chaque souche bactérienne obtenus en milieu solide et/ou en milieu liquide sont mélangés dans des proportions appropriées pour obtenir les médicaments selon la revendication 1. Les quantités de germes des souches utilisées en association peuvent varier entre certaines limites pour une prise journalière humaine (adulte) : de 1 à 50 milliards de germes. The lysates of each bacterial strain obtained in solid medium and / or in liquid medium are mixed in suitable proportions to obtain the medicaments according to claim 1. The amounts of germs of the strains used in association can vary between certain limits for a daily human intake (adult): from 1 to 50 billion germs.

Le mélange des lysats constitue un concentré natif qui est clarifié par centrifugation et filtration en profondeur. Le concentré clarifié est stérilisé par filtration sur membrane et constitue le concentré de lysats bactériens servant de base à la préparation des différentes formes galéniques. The mixture of lysates constitutes a native concentrate which is clarified by centrifugation and deep filtration. The clarified concentrate is sterilized by membrane filtration and constitutes the concentrate of bacterial lysates serving as a basis for the preparation of the various dosage forms.

Formes galéniques Dosage forms

L'administration se fait de préférence par voie orale, sous forme de comprimés, capsules, gélules, granulés, contenant le lysat sous forme lyophilisée ou de soluté buvable sous forme d'ampoules monodoses de sirop ou de gouttes contenant le lysat. L'administration peut également se faire par voie parentérale, ou encore par voie rectale sous forme de suppositoires. La dose journalière pour un adulte, prise de préférence en une fois, peut contenir au total un lysat variant entre 1 et 50 milliards d'équivalents-germes. The administration is preferably carried out orally, in the form of tablets, capsules, capsules, granules, containing the lysate in lyophilized form or oral solution in the form of single-dose ampoules of syrup or drops containing the lysate. Administration can also be done parenterally, or rectally in the form of suppositories. The daily dose for an adult, preferably taken at once, may contain a total of a lysate varying between 1 and 50 billion germ equivalents.

La dose enfant est la moitié de la dose adulte. The child dose is half the adult dose.

Une étude expérimentale de l'état immunitaire a été effectuée chez la souris Balb/c après stimulation orale par le lysat défini selon les revendications 1 et 2. Cette étude couvre l'immunité à médiation humorale et l'immunité à médiation cellulaire, tant spécifique que non spécifique. An experimental study of the immune state was carried out in Balb / c mice after oral stimulation with the lysate defined according to claims 1 and 2. This study covers humoral and cell-mediated immunity, both specific than non-specific.

Test de protection Protection test

Les souris ont été traitées par voie orale avec 150 mg/kg pendant 5 d. Il a été montré que le lysat a un pouvoir protecteur statistiquement significatif vis-à-vis d'une infection par Escherichia coli injecté par voie intrapéritonéale 10 et 30 d après le début du traitement, ou par Salmonella typhimurium inoculé par voie entérale 30 d après le début du traitement. The mice were treated orally with 150 mg / kg for 5 d. The lysate has been shown to have a statistically significant protective power against infection by Escherichia coli injected intraperitoneally 10 and 30 d after the start of treatment, or by Salmonella typhimurium inoculated by enteral route 30 d the start of treatment.

Test Plaque forming Cells Plate forming cells test

Cette technique a permis de montrer une augmentation en fonction du temps du nombre de cellules spléniques produisant des plaques de lyse chez les souris traitées avec 150 mg/kg de lysat, pendant 5 d, par voie orale. Le test a été effectué 14 d après le début du traitement. This technique made it possible to show an increase as a function of time in the number of spleen cells producing lysis plaques in mice treated with 150 mg / kg of lysate, for 5 d, orally. The test was performed 14 after the start of treatment.

Test de phagocytose in vivo au carbone colloïdal In vivo colloidal carbon phagocytosis test

Le carbone colloïdal injecté à une souris est éliminé du système vasculaire par les cellules de Küpffer. La cinétique d'élimination du colloïde est donc le reflet de l'activité du système réticulo-endothélial. On a traité des souris par voie orale pendant 5 d avec 150 mg/kg de lysat. 10 et 30 d après le début du traitement, le test est réalisé. L'indice phagocytaire est augmenté de façon statistiquement significative. The colloidal carbon injected into a mouse is eliminated from the vascular system by Küpffer's cells. The colloid elimination kinetics therefore reflect the activity of the reticuloendothelial system. Mice were treated orally for 5 d with 150 mg / kg lysate. 10 and 30 d after the start of treatment, the test is carried out. The phagocytic index is statistically significantly increased.

Etude de l'activité des macrophages Study of macrophage activity

Des souris ont été traitées avec 150 mg/kg de lysat par voie orale pendant 5 d. Les macrophages intrapéritonéaux ont été prélevés 10 et 30 d après le début du traitement. Mice were treated with 150 mg / kg of oral lysate for 5 d. The intraperitoneal macrophages were removed 10 and 30 days after the start of treatment.

L'étude des capacités d'adhérence et de phagocytose in vitro (Candida albicans) des macrophages a montré que le lysat utilisé a une action immunostimulante au niveau cellulaire. The study of the adhesion and phagocytosis capacities in vitro (Candida albicans) of macrophages has shown that the lysate used has an immunostimulatory action at the cellular level.

Il a également été montré une chute caractéristique des activités enzymatiques de ces macrophages due probablement à un épuisement de ces cellules trop sollicitées. Des contrôles effectués en microscopie électronique de transmission ont pu confirmer cette hypothèse; les macrophages activés présentent de fortes vacuolisations. A characteristic drop in the enzymatic activities of these macrophages has also been shown, probably due to an exhaustion of these over-stressed cells. Transmission electron microscopy checks were able to confirm this hypothesis; activated macrophages show strong vacuolations.

5 5

10 10

15 15

20 20

25 25

30 30

35 35

40 40

45 45

50 50

55 55

60 60

65 65

3 3

639 852 639,852

Etude de la toxicité chronique Chronic toxicity study

Le lysat a été administré à des doses de 100 et 1000 fois la dose thérapeutique humaine à des rats, et à des doses de 20 et 200 fois à des chiens par voie orale pendant 13 semaines. The lysate was administered at doses 100 and 1000 times the human therapeutic dose to rats, and at doses 20 and 200 times to dogs orally for 13 weeks.

Aucune altération fonctionnelle ou organique n'a été décelée au cours du traitement. No functional or organic changes were detected during treatment.

Essais cliniques Clinical tests

17 malades souffrant d'infection urinaire chronique ont été traités à raison de 1 dose par jour de lysat pendant 8-12 mois à raison de 10 à 15 d de traitement par mois. Les récidives ont été totalement 5 éliminées dans 14 cas et espacées dans 3 cas. 17 patients with chronic urinary tract infection were treated with 1 dose per day of lysate for 8-12 months at the rate of 10 to 15 d of treatment per month. Recurrences were completely eliminated in 14 cases and spaced out in 3 cases.

R R

Claims (6)

639 852639,852 1. Médicament immunobiothêrapique contre les maladies infectieuses des voies urinaires et digestives, contenant comme principe actif un lysat bactérien provenant d'au moins une des souches suivantes à'Escherichia coli: 1. Immunobiotherapeutic drug against infectious diseases of the urinary and digestive tract, containing as active ingredient a bacterial lysate from at least one of the following strains of Escherichia coli: — NCTC; 8603, 8621, 8622, 8623, 9026, 9111, 9119, 9707, 9708. - NCTC; 8603, 8621, 8622, 8623, 9026, 9111, 9119, 9707, 9708. — CNCM: 1-081,1-082,1-083,1-084,1-085,1-086,1-087,1-088, 1-089. - CNCM: 1-081,1-082,1-083,1-084,1-085,1-086,1-087,1-088, 1-089. 2. Médicament selon la revendication 1, caractérisé par le fait que ledit principe actif et constitué par un mélange de lysats de toutes les souches mentionnées. 2. Medicament according to claim 1, characterized in that said active principle and consisting of a mixture of lysates of all the strains mentioned. 2 2 REVENDICATIONS 3. Procédé de fabrication d'un médicament selon l'une des revendications 1 ou 2, caractérisé par le fait que lesdites souches sont incubées dans un milieu de culture solide ou liquide, qu'elles subissent une lyse et/ou une autolyse, et qu'on récolte les lysats ainsi obtenus. 3. Method for manufacturing a medicament according to one of claims 1 or 2, characterized in that the said strains are incubated in a solid or liquid culture medium, that they undergo lysis and / or autolysis, and that the lysates thus obtained are harvested. 4. Milieu de culture pour exécuter le procédé selon la revendication 3, contenant par litre d'eau: extrait de viande 22,5 g, extrait de levure 7,5 g, chlorure de sodium 2,5 g, acétate de sodium 0,5 g, mo-nohydrogénophosphate de sodium 2,0 g, lactate de sodium 70% p/p 2,0 ml, lactate d'ammonium 50% p/p 2,0 ml, aneurine 3,0 mg, acide nicotinique 3,0 mg, glucose 3,0 g, ces chiffres pouvant varier de 4. Culture medium for carrying out the process according to claim 3, containing per liter of water: meat extract 22.5 g, yeast extract 7.5 g, sodium chloride 2.5 g, sodium acetate 0, 5 g, sodium mo-nohydrogen phosphate 2.0 g, sodium lactate 70% w / w 2.0 ml, ammonium lactate 50% w / w 2.0 ml, aneurine 3.0 mg, nicotinic acid 3, 0 mg, glucose 3.0 g, these figures may vary from 5. Milieu selon la revendication 4, contenant en plus, par litre d'eau: gélatine 2,0 g et gélose 24,0 g, afin de le rendre solide. 5. Medium according to claim 4, containing in addition, per liter of water: gelatin 2.0 g and agar 24.0 g, in order to make it solid. ± 5%. ± 5%. 6. Milieu de culture liquide pour exécuter le procédé selon la revendication 3, par autolyse, contenant, par litre d'eau: extrait de viande 25,0 g, chlorure de sodium 5,0 g, monohydrogénophosphate de sodium 1,0 g, ces chiffres pouvant varier de + 5%. 6. Liquid culture medium for carrying out the process according to claim 3, by autolysis, containing, per liter of water: meat extract 25.0 g, sodium chloride 5.0 g, sodium monohydrogen phosphate 1.0 g, these figures can vary by + 5%.
CH692479A 1979-07-26 1979-07-26 MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS. CH639852A5 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CH692479A CH639852A5 (en) 1979-07-26 1979-07-26 MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS.
DE19803019448 DE3019448A1 (en) 1979-07-26 1980-05-21 IMMUNOBIOTHERAPEUTICAL MEDICINAL PRODUCT AND METHOD FOR THE PRODUCTION THEREOF
ES491920A ES491920A0 (en) 1979-07-26 1980-05-28 PROCEDURE FOR THE PREPARATION OF IMMUNOBIO-THERAPIC MEDICINES FROM MICROBIOLOGICAL STRAINS.
FR8012677A FR2462164A1 (en) 1979-07-26 1980-06-06 MEDICAMENT FOR INFECTIOUS DISEASES OF THE URINATING AND DIGESTIVE PATHWAYS BASED ON A BACTERIAL LYSATE FROM AT LEAST ONE STRAIN OF ESCHERICHIA COLI
HU801726A HU181725B (en) 1979-07-26 1980-07-10 Process for producing immunotherapeutic pharmaceutical composition
DD222593A DD153192A5 (en) 1979-07-26 1980-07-14 PROCESS FOR PREPARING AN IMMUNOBIOTHERAPEUTIC DRUG DISPARATE
RO80101780A RO80054A (en) 1979-07-26 1980-07-22 PROCESS FOR OBTAINING A MEDICAMENT FOR INFECTION AFFECTED BY URINARY AND DIGESTIVE PATHWAYS
IT49314/80A IT1143025B (en) 1979-07-26 1980-07-24 DRUG AGAINST URINARY AND DIGESTIVE TRACT INFECTIOUS DISEASES AND PROCEDURE TO PRODUCE IT
BE0/201514A BE884456A (en) 1979-07-26 1980-07-24 MEDICINE FOR INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS
PL1980225853A PL127520B1 (en) 1979-07-26 1980-07-24 Process for preparing medicine against infectious diseases of urinary and gastro-intestinal tracts
AR281940A AR222887A1 (en) 1979-07-26 1980-07-25 PROCEDURE FOR THE PREPARATION OF AN IMMUNOBIOTHERAPIC MEDICINE AND A CULTIVATION MEDIA TO PUT IT INTO PRACTICE
CS805266A CS212234B2 (en) 1979-07-26 1980-07-25 Method of making the immunotherapeutical means against the infection decease uf urine and digesting ways
YU1896/80A YU42532B (en) 1979-07-26 1980-07-25 Process for obtaining bacteria lizate from cultures of escherichia coli
JP10231580A JPS5622733A (en) 1979-07-26 1980-07-25 Immunity creature therapeutic drug and its manufacture
GB8024420A GB2054374B (en) 1979-07-26 1980-07-25 Bacterial lysates
PT71612A PT71612A (en) 1979-07-26 1980-07-25 PROCESS FOR THE PREPARATION OF A MEDICAMENT AGAINST INFECTIOUS DISEASES OF URINARY AND DIGESTIVE PATHWAYS
HRP-1896/80A HRP921282B1 (en) 1979-07-26 1992-11-16 Process for obtaining bacterial lisate from the sorts of escherichia coli

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH692479A CH639852A5 (en) 1979-07-26 1979-07-26 MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS.

Publications (1)

Publication Number Publication Date
CH639852A5 true CH639852A5 (en) 1983-12-15

Family

ID=4317195

Family Applications (1)

Application Number Title Priority Date Filing Date
CH692479A CH639852A5 (en) 1979-07-26 1979-07-26 MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS.

Country Status (16)

Country Link
JP (1) JPS5622733A (en)
AR (1) AR222887A1 (en)
BE (1) BE884456A (en)
CH (1) CH639852A5 (en)
CS (1) CS212234B2 (en)
DD (1) DD153192A5 (en)
DE (1) DE3019448A1 (en)
ES (1) ES491920A0 (en)
FR (1) FR2462164A1 (en)
GB (1) GB2054374B (en)
HU (1) HU181725B (en)
IT (1) IT1143025B (en)
PL (1) PL127520B1 (en)
PT (1) PT71612A (en)
RO (1) RO80054A (en)
YU (1) YU42532B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2550707B1 (en) * 1983-08-17 1986-02-28 Lipha IMMUNOMODULATOR OF BIOLOGICAL MEDICINE AND PROCESS FOR PREPARING THE SAME
US4740585A (en) * 1984-07-30 1988-04-26 The Board Of Trustees Of The Leland Stanford Junior University Synthetic vaccine against urinary infections
EP1641488B1 (en) 2003-06-23 2011-03-30 Biotech Tools S.A. Epitope composition for enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin
CA2679983C (en) * 2007-03-05 2018-10-02 Om Pharma Bacterial extract for digestive or urinary tract disorders and process for its preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1336015A (en) * 1970-06-03 1973-11-07 Unilever Ltd Rearing pigs
US3911109A (en) * 1971-10-14 1975-10-07 Lever Brothers Ltd Rearing calves
BE789864A (en) * 1971-10-14 1973-04-09 Unilever Nv CALF BREEDING
JPS5219927B2 (en) * 1972-06-08 1977-05-31
GB1462384A (en) * 1973-04-12 1977-01-26 Unilever Ltd Rearing of lambs
GB1560934A (en) * 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders
US4141970A (en) * 1975-05-07 1979-02-27 Internationale Octrooimaatschappij "Octropa" B.V. Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
GB1581776A (en) * 1976-08-18 1980-12-17 Smith Kline Rit Vaccines against oedema disease of piglets

Also Published As

Publication number Publication date
RO80054A (en) 1982-10-26
JPH0255407B2 (en) 1990-11-27
ES8104402A1 (en) 1981-04-01
IT1143025B (en) 1986-10-22
CS212234B2 (en) 1982-03-26
FR2462164B1 (en) 1983-08-05
YU42532B (en) 1988-10-31
GB2054374A (en) 1981-02-18
DE3019448C2 (en) 1987-07-30
ES491920A0 (en) 1981-04-01
HU181725B (en) 1983-11-28
DE3019448A1 (en) 1981-02-12
AR222887A1 (en) 1981-06-30
PL127520B1 (en) 1983-11-30
GB2054374B (en) 1983-06-22
YU189680A (en) 1983-06-30
JPS5622733A (en) 1981-03-03
PL225853A1 (en) 1981-05-08
BE884456A (en) 1980-11-17
DD153192A5 (en) 1981-12-30
PT71612A (en) 1980-08-01
IT8049314A0 (en) 1980-07-24
FR2462164A1 (en) 1981-02-13

Similar Documents

Publication Publication Date Title
US4710379A (en) Intestinal microflora-improving agent
Gyaurgieva et al. Meningitis caused by Rhodotorula rubra in an HIV-infected patient
TW200538047A (en) A composition having immunoregulating activities
EP0001945B1 (en) Polysaccharides extracted from microbial cells of haemophilus influenzae, process for their preparation and pharmaceutical compositions containing them
JP2000256202A (en) Novel organism depuration active form lactic acid bacterium preparation
JPWO2005077390A1 (en) Glucose level lowering agent, diabetes treatment / prevention agent and method for producing the same
CH639852A5 (en) MEDICINE AGAINST INFECTIOUS DISEASES OF THE URINARY AND DIGESTIVE PATHWAYS.
Ferraz et al. Rothia dentocariosa endocarditis and aortic root abscess
WO1998056755A1 (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
EP3017069B1 (en) Use of a bacterium isolated from the genus pseudoalteromonas, cyclolipopeptides and uses thereof
JPS6320807B2 (en)
CH620691A5 (en)
JP2969017B2 (en) Infection protective agent
FR2658419A1 (en) MEDICAMENT FOR THE TREATMENT OF DERMATITIS.
CH633188A5 (en) MEDICINE FOR INFECTIOUS DISEASES OF THE RESPIRATORY TRACT.
EP0148025A2 (en) Antibodies and antibody-containing compositions for inhibiting periodontitis
JP7152733B2 (en) cancer metastasis inhibitor
EP0139551B1 (en) Immunomodulating medicine of biological origin, and process for preparing it
JPH08283166A (en) Prophylactic agent
EP0600915B1 (en) Box-based composition for treating hiv (human immunodeficiency virus) infection
FR2536281A1 (en) PHARMACEUTICAL COMPOSITIONS FOR REGULATING PHAGOCYTIC FUNCTIONS
EP1869195A2 (en) Macromolecule obtained from a bifidobacterium culture and use thereof for the prevention and treatment of inflammatory rheumatisms
JPH07238024A (en) Neutrophile function improver
JP2024102776A (en) Preventing/alleviating material of diarrhea/loose passage
KR920005685B1 (en) Anti-tumoric agent from lactobacillus sporogenes

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate filed

Free format text: OICM 46600/871014

NV New agent

Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS

SPCG Supplementary protection certificate granted

Free format text: OICM 46600/871014, 960209, EXPIRES:20021014

PL Patent ceased